Abstract
The current organ shortage scenario has prompted the increasing use of high-risk donor livers. These include livers from elderly donors, which have been convincingly shown to have an unfavorable impact on liver transplantation of hepatitis C virus (HCV)-infected patients. In addition, other donor-related risk factors include an unfavorable pattern of IL28B genotype, the donation after cardiac death (DCD), and the previous exposure of donors to hepatitis viruses. On the other hand, recipient-related risk factors in HCV-positive patients include ethnicity, female gender, again the pattern of IL28B genotype (CT or TT), and the presence of an HIV coinfection. Based on these data, the following recommendations can be made: First, grafts from donors aged > 70 years (in the Italian scenario) and, possibly, aged > 60 years (in other settings) should not be allocated to HCV-positive recipients. This policy is difficult, but can be implemented, and should be strongly encouraged, unless when it is plausible that it could lead to increased waiting list mortality. Second, great attention should be paid to donor–recipient matching in well-compensated HCV-positive recipients carrying hepatocellular carcinoma (HCC) within Milan criteria, in whom the final prognosis can be dramatically influenced by the age of the donor. If an elderly donor is being used, one should always carefully consider how to best balance the risk of dying/dropping out from the list because of HCC progression before liver transplantation (LT) and the risk of severe recurrence of HCV after LT. There are no data as yet to provide an evidence-based solution to this crucial issue, thus the decision should rely on a thorough and judicious clinical evaluation of both risks. Finally, some gender combinations may be deleterious in HCV-positive recipients and, accordingly, transplanting a male donor graft into a female recipient should be considered with caution, not only in the case of an elderly donor.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.
Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7:567–80.
Merion RM. Current status and future of liver transplantation. Semin Liver Dis. 2010;30:411–21.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889.
Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226–31.
Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9:651–63.
Merion RM, Goodrich NP, Feng S. How can we define expanded criteria for liver donors? Hepatology. 2006;45:484–8.
Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Digest Liver Dis. 2011;43:155–14.
Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation. 2006;81:7–14.
Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783–90.
Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post-transplant mortality for optimization of donor-recipient matching. Am J Transplant. 2009;9:318–26.
Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, et al. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. Am J Transplant. 2011;11:2724–36.
Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology. 2003;38:34–41.
Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248–52.
Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl. 2008;14:1694–707.
Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, et al. IL28B in the donor CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int. 2013 Jan;33(1):72–8. doi:10.1111/liv.12013.
Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91:1265–72.
Angelico M. Donor liver steatosis and graft selection for liver transplantation: a short review. Eur Rev Med Pharmacol Sci. 2005;9:295–7.
Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013;58(4):715–23. pii: S0168-8278(12)00894-X. doi:10.1016/j.jhep.2012.11.025.
Tao R, Ruppert K, Cruz RJ Jr, Malik SM, Shaikh O, Ahmad J, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl. 2010;6:1288–95.
Layden JE, Cotler S, Brown KA, Lucey MR, Te HS, Eswaran S, et al. Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation. 2012;94:178–84.
Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;49:825–32.
Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Camma C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 2007;13:733–40.
Lai JC, Verna EC, Brown RS Jr, O’Leary JG, Trotter JF, Forman LM, et al. Hepatitis C virus-infected women have high risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54:418–24.
Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 2012;18:671–9.
Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C infection. Hepatology. 2011;53:317–24.
Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716–26.
Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation. 2012;93:723–8.
Angelico M, Marianelli T, Ginanni Corradini S, Gavrila C, Miglioresi L, Sforza D, Ettorre GM, Gerunda GM, Rossi M, Tisone G, Nardi M. The use of cytomegalovirus (CMV)-negative donors older than 60 years is selectively associated with poor post-transplantation outcomes in CMV-positive recipients: an age-related cause of latent CMV reactivation? J Hepatol. 2013 (EASL abstract).
Lai JC, Feng S, Roberts JP, Terrault NA. Gender differences in liver donor quality are predictive of graft loss. Am J Transplant. 2011;11:296–302.
Romagnoli R, Rossi M, Gerunda GE, Pinna A, Agnes S, Tisone G, et al. Graft survival is significantly worst in HCV-infected liver transplanted females receiving an organ from male donors: results from the Liver Match study. Liver Transpl. 2012 (ILTS abstract).
Acknowledgment
The authors wish to thank Prof. Alessandra Nardi and Dr. Caius Gavrila for providing the figures and the updated results of the Liver Match Study.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Angelico, M., Lenci, I. (2014). Donor–Recipient Matching in HCV-Infected Patients. In: Berenguer, M. (eds) Hepatitis C Virus and Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8438-7_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8438-7_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8437-0
Online ISBN: 978-1-4614-8438-7
eBook Packages: MedicineMedicine (R0)